Welling, Lindsey; Waisbren, Susan E; Antshel, Kevin M; Colhoun, Hugh-Owen; Gautschi, Matthias; Grünewald, Stephanie; Holman, Rebecca; van der Lee, Johanna H; Treacy, Eileen P; Bosch, Annet M (2017). Systematic Review and Meta-analysis of Intelligence Quotient in Early-Treated Individuals with Classical Galactosemia. JIMD reports, 37, pp. 115-123. Springer 10.1007/8904_2017_22
Text
978-3-662-56359-5_Chapter_22.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (259kB) |
INTRODUCTION
Cognitive impairment is a well-known complication of classical galactosemia (CG). Differences in patient characteristics and test methods have hampered final conclusions regarding the extent of intellectual disabilities in CG. The primary aim of this systematic review was to assess intellectual performance in early-treated (≤4 weeks of life) individuals with confirmed CG (defined by absent or barely detectable GALT enzyme activity and/or the presence of two null or severe missense variations), assessed with comparable test instruments. The full-scale IQ (FSIQ) was the variable of interest.
METHODS
A clinical librarian developed search strategies, and two independent investigators performed the study selection, risk of bias assessment and data extraction. Individual patient data were pooled for meta-analysis using linear mixed-effect models with a random intercept per study and including covariates (age or gender) as fixed effects where appropriate.
RESULTS
Four articles were included in this meta-analysis. Data of 87 individuals (median age 13 years, range 3-38 years) were used to assess mean FSIQ in CG. The FSIQ ranged from 47 to 122, and the mean score was 87 (95% CI, 81-94). Forty-five percent of individuals attained scores <85, almost 40% attained scores of 85-100, and a minority (15%) attained scores above 100. There was no significant correlation between FSIQ and age.
CONCLUSIONS
Results from this meta-analysis fortify conclusions from previous studies that early-treated individuals with CG are at risk for having impaired cognitive abilities. However, IQ varies considerably between affected individuals.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Institute of Clinical Chemistry 04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Paediatric Medicine |
UniBE Contributor: |
Gautschi, Matthias |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
2192-8304 |
Publisher: |
Springer |
Language: |
English |
Submitter: |
Anette van Dorland |
Date Deposited: |
26 Mar 2018 16:46 |
Last Modified: |
05 Dec 2022 15:10 |
Publisher DOI: |
10.1007/8904_2017_22 |
PubMed ID: |
28391442 |
Uncontrolled Keywords: |
Classical galactosemia Cognition Intelligence quotient Meta-analysis Neuropsychological tests Review |
BORIS DOI: |
10.7892/boris.111432 |
URI: |
https://boris.unibe.ch/id/eprint/111432 |